CLOs on the Move

Ra Medical

www.ramed.com

 
Advanced Excimer Laser-Based Vascular and Dermatological Therapies We are a medical device company leveraging our advanced excimer laser-based platform for use in the treatment of vascular and dermatological diseases. We believe our products enhance patients` quality of life by restoring blood-flow in arteries and clearing chronic skin conditions. We currently manufacture and market two lines of products: DABRA Catheter and Laser is cleared by the U.S. FDA as a tool for the minimally invasive endovascular treatment of vascular blockages resulting from lower extremity vascular disease, including peripheral artery disease (PAD) and critical limb ischemia (CLI). Pharos Excimer Laser is FDA ...
  • Number of Employees: 25-100
  • Annual Revenue: $10-50 Million
  • www.ramed.com
  • 2070 Las Palmas Drive
    Carlsbad, CA USA 92011
  • Phone: 760.804.1648

Executives

Name Title Contact Details
Daniel Horwood
General Counsel Profile
Daniel Horwood
General Counsel Profile

Similar Companies

GroupOne Healthsource

GroupOne Healthsource is a Jefferson City, MO-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Lifeblood Mid South Regional Blood Center

Lifeblood opens the East Donor Center on Estate Drive. In 1954, another proposal to establish a blood center in Memphis was rejected for the same reason-it was too costly. Finally in 1962, the Committee on Blood Bank Operation of the Memphis and Shelby

Triad Healthcare

Triad Healthcare Inc. is one of the leading companies in Healthcare, Pharmaceuticals, & Biotech industry. Triad Healthcare Inc. is based in Plainville, CT. You can find more information on Triad Healthcare Inc. at www.triadhealthcareinc.com

Blueprint Medicines

Blueprint Medicines is developing a new generation of highly selective and potent kinase therapies to dramatically improve the lives of patients with genomically defined diseases. Our approach is rooted in a deep understanding of the genetic blueprint of cancer and other diseases driven by the abnormal activation of kinases. Our ability to identify novel drivers of disease, coupled with our proprietary library of novel and diverse chemical compounds, uniquely enables us to craft kinase therapies against new and difficult-to-drug targets. We are boldly advancing a deep pipeline of highly targeted therapies against previously unaddressed drivers of disease. By focusing on genomically defined subsets of patients, we believe we can identify the people most likely to respond to our therapies, resulting in a more efficient clinical development path with a greater likelihood of success and better outcomes for patients. We see a substantial opportunity in kinase drug discovery and development to deliver breakthrough medicines that allow patients to live longer with better quality of life and prevent recurrences of disease. Kinases are involved in many hallmarks of tumor biology and are proven cancer drug targets. Currently approved drugs focus on less than 5 percent of known kinases, and the function of most kinases is unknown. Led by a team of industry innovators with a track record of bringing life-changing drugs to market, we believe Blueprint Medicines has the experience and expertise to deliver on the tremendous untapped potential of kinase therapies to improve patients’ lives. We don’t think in small steps. We think in giant leaps. We are driven by the pursuit of new ideas, new innovations, and new ways of thinking.

Clipper America Inc

Clipper America Inc is a Houston, TX-based company in the Healthcare, Pharmaceuticals, & Biotech sector.